Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bone Marrow Transplant Rejection - Overview
Bone Marrow Transplant Rejection - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Marrow Transplant Rejection - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development
Bone Marrow Transplant Rejection - Drug Profiles
Bone Marrow Transplant Rejection - Dormant Projects
Bone Marrow Transplant Rejection - Discontinued Products
Bone Marrow Transplant Rejection - Product Development Milestones
Featured News & Press Releases
Apr 25, 2022: Equillium announces three poster presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
Apr 25, 2022: Orca Bio presents positive data reinforcing clinical profile and manufacturing reliability of Orca-T at 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings
Apr 21, 2022: INRAE and MaaT Pharma build on the success of their long-standing partnership with the entry of drug-candidate MaaT013 into phase 3 clinical trial
Apr 21, 2022: Rezurock (belumosudil) patient-reported outcomes correlated with clinical response in chronic graft-versus-host disease
Apr 04, 2022: Equillium announces oral presentation at the Italian Society of Experimental Hematology
Mar 28, 2022: MaaT Pharma announces first patient dosed in phase 3 ?ARES’ trial evaluating MaaT013 in patients with acute Graft-vs-Host-Disease
Mar 25, 2022: Incyte announces positive CHMP opinion for ruxolitinib (Jakavi) for the treatment of acute and chronic graft-versus-host disease
Mar 23, 2022: Equillium announces two oral presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
Mar 23, 2022: VectivBio presents preclinical data supporting Apraglutide for treatment of Acute Graft-Versus-Host Disease at the 48th annual meeting of the European Society for Blood and Marrow Transplantation
Mar 18, 2022: Seres Therapeutics presents preclinical research on investigatiol microbiome therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
Mar 17, 2022: MaaT Pharma to present promising clinical data for lead therapeutic candidate MaaT013 at 48th EBMT Annual Meeting
Mar 07, 2022: Equillium begins Phase III acute graft-versus-host disease trial
Feb 28, 2022: AbbVie seeks new indication for IMBRUVICA (ibrutinib) in pediatric patients with chronic graft versus host disease (cGVHD)
Feb 17, 2022: Veloxis Pharmaceuticals’ VEL-101 Granted FDA Fast Track Desigtion
Feb 01, 2022: FDA approves abatacept for prophylaxis of acute graft versus host disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Bone Marrow Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Bone Marrow Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Bone Marrow Transplant Rejection - Dormant Projects, 2022
Bone Marrow Transplant Rejection - Discontinued Products, 2022